Technical Analysis for EXEL - Exelixis, Inc.

Grade Last Price % Change Price Change
grade C 19.82 -2.46% -0.50
EXEL closed down 2.46 percent on Friday, January 17, 2020, on 84 percent of normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a pullback should not be unexpected.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up
Historical EXEL trend table...

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Upper Bollinger Band Walk Strength 0.00%
Multiple of Ten Bearish Other 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Spinning Top Other -2.46%
Upper Bollinger Band Walk Strength -2.46%
Above Upper BB Strength -2.46%
Overbought Stochastic Strength -2.46%

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Exelixis, Inc., a biotechnology company, engages in developing small molecule therapies for the treatment of cancer in the United States. It focuses on developing and commercializing COMETRIQ (cabozantinib), an inhibitor of multiple receptor tyrosine kinases for the treatment of progressive, metastatic medullary thyroid cancer. COMETRIQ is also involved in various other cancer indications, including two ongoing Phase III pivotal trials in metastatic castration-resistant prostate cancer; and two additional Phase III pivotal trials in metastatic hepatocellular cancer and metastatic renal cell cancer. In addition, the company has a portfolio of other novel compounds that address serious unmet medical needs. Exelixis, Inc. has collaborations with Bristol-Myers Squibb Company, Sanofi, Genentech, Inc., GlaxoSmithKline, Merck, and Daiichi Sankyo Company Limited for the development and commercialization of various compounds. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was founded in 1994 and is headquartered in South San Francisco, California.
Chemistry Biotechnology Cancer Treatment Of Cancer Cyclopropanes Sanofi Tyrosine Kinase Inhibitors Protein Kinase Inhibitor Genentech Small Molecule Therapies Metastatic Castration Resistant Prostate Cancer

Is EXEL a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 25.31
52 Week Low 15.02
Average Volume 2,972,541
200-Day Moving Average 19.26
50-Day Moving Average 17.49
20-Day Moving Average 18.61
10-Day Moving Average 19.08
Average True Range 0.75
ADX 19.28
+DI 31.20
-DI 21.16
Chandelier Exit (Long, 3 ATRs ) 18.50
Chandelier Exit (Short, 3 ATRs ) 18.95
Upper Bollinger Band 20.38
Lower Bollinger Band 16.84
Percent B (%b) 0.84
BandWidth 19.02
MACD Line 0.62
MACD Signal Line 0.45
MACD Histogram 0.1755
Fundamentals Value
Market Cap 5.83 Billion
Num Shares 294 Million
EPS 0.20
Price-to-Earnings (P/E) Ratio 99.10
Price-to-Sales 23.83
Price-to-Book 51.23
PEG Ratio 2.01
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 21.01
Resistance 3 (R3) 21.12 20.85 20.81
Resistance 2 (R2) 20.85 20.54 20.79 20.74
Resistance 1 (R1) 20.33 20.36 20.20 20.22 20.68
Pivot Point 20.06 20.06 19.99 20.00 20.06
Support 1 (S1) 19.54 19.75 19.41 19.43 18.96
Support 2 (S2) 19.27 19.57 19.21 18.90
Support 3 (S3) 18.75 19.27 18.83
Support 4 (S4) 18.64